
2026 年 12月4–6日,欧洲肿瘤内科学会亚洲年会(ESMO Asia Congress 2026)将在新加坡举办。作为亚太地区肿瘤领域重要学术盛会,本届大会收录多项胸部肿瘤壁报研究,覆盖早期筛查、围手术期管理、靶向耐药、免疫治疗、生物标志物探索及真实世界证据等方向,中国学者贡献颇丰。医脉通对中国学者胸部肿瘤相关壁报摘要进行系统整理,以飨读者。
早期胸部肿瘤
摘要号:896P
研究名称(英文):Integrative Tissue and Plasma Proteomics Reveals Molecular Features and Age-Related Differences in Early-Onset Lung Cancer
研究名称(中文):整合组织和血浆蛋白质组学揭示早发性肺癌的分子特征及年龄相关差异
讲者:Ruolin Gao|北京,中国
摘要号:897P
研究名称(英文):Incidence and Timing of Incident Lung-RADS ≥3 Nodules After Baseline-Negative LDCT in Health-Checkup Cohorts
研究名称(中文):基线阴性低剂量CT健康检查队列中新发Lung-RADS ≥3类结节的发生率及时间
讲者:Jingwen Diao|广州,中国
摘要号:898P
研究名称(英文):From stage shift to mortality reduction: real-world evidence of lung adenocarcinoma screening in Taiwan, 2011–2023
研究名称(中文):从分期迁移到死亡率降低:台湾2011–2023年肺腺癌筛查的真实世界证据
讲者:Ruru Chun-Ju Chiang|台北,中国台湾
摘要号:901P
研究名称(英文):Injection-Tip-to-Thoracoscopic-Pleura Distance Predicts Fluorescence Intensity in CT-Guided ICG Localization of Pulmonary Nodules
研究名称(中文):注射针尖至胸腔镜胸膜距离预测CT引导下ICG定位
讲者:Chen-Sung Lin|新北市,中国台湾
摘要号:902P
研究名称(英文):PLEDGE: A Pleura-Oriented, Tumor-Edge-Driven Multi-Evidence CT Framework for Preoperative Prediction of Visceral Pleural Invasion in Non-Small Cell Lung Cancer
研究名称(中文):PLEDGE:一种胸膜导向、肿瘤边缘驱动的多证据CT框架,用于
讲者:Xuhua Huang|杭州,中国
摘要号:903P
研究名称(英文):"Double Helix" Effects of Outdoor Air Pollution and Smoking on Lung Cancer Risk: Insights from Proteomic Analysis Based on a Large-Scale Prospective Population Cohort and Independent Real-World Validation
研究名称(中文):“双螺旋”效应:室外空气污染与吸烟对肺癌风险的影响:基于大规模前瞻性人群队列及独立真实世界验证的蛋白质组学分析见解
讲者:Yuxuan Liao|北京,中国
摘要号:904P
研究名称(英文):An Interpretable Multi-Modal AI Framework Integrating 3D Deep Learning and Radiomics for Predicting Visceral Pleural Invasion in ≤3 cm Non-Small Cell Lung Cancer: A Retrospective Two-Centre Study
研究名称(中文):用于预测≤3 cm非小细胞肺癌脏层胸膜侵犯的可解释多模态AI框架整合3D深度学习与影像组学:一项回顾性双中心研究
讲者:Liqing Li|南宁,中国
摘要号:906P
研究名称(英文):A Prospective Study on Artificial Intelligence guided Lung Cancer Screening for High-risk Never Smokers in Hong Kong: Baseline results of the LC-SHIELD study
研究名称(中文):一项关于人工智能引导肺癌筛查的高危从不吸烟人群的前瞻性研究:LC-SHIELD研究基线结果
讲者:Molly Li|香港,中国香港
摘要号:910P
研究名称(英文):Preserving lung function in the era of sublobar resection for early-stage lung cancer: three-month pulmonary function after wedge resection, segmentectomy, and lobectomy
研究名称(中文):在亚肺叶切除时代保护肺功能:早期肺癌楔形切除、肺段切除和肺叶切除术后三个月肺功能
讲者:Qicong Chen|广州,中国
摘要号:911P
研究名称(英文):Neoadjuvant lorlatinib in resectable stage IB-IIIB ALK-rearranged NSCLC: Simon stage 1 analysis of NEOLORA study
研究名称(中文):新辅助
讲者:Heng Zhao|北京,中国
摘要号:913P
研究名称(英文):Associations of oncogenic drivers with IASLC grade and spread through air spaces in resected non-mucinous lung adenocarcinoma
研究名称(中文):切除非黏液性肺腺癌中驱动基因与IASLC分级及沿气道扩散的关联
讲者:Lifeng Wang|重庆,中国
摘要号:914P
研究名称(英文):Adjuvant Third-Generation EGFR-TKI Improves Relapse-Free Survival in Completely Resected Stage I Non-Small Cell Lung Cancer: A Multicenter Real-World Cohort Study
研究名称(中文):辅助第三代EGFR-TKI改善完全切除的I期非小细胞肺癌的无复发生存期:一项多中心真实世界队列研究
讲者:Longfei Wang|宁波,中国
摘要号:915P
研究名称(英文):PAXOS (China) - Adherence and Persistence to Adjuvant Osimertinib Among Patients with Early-stage Non-small Cell Lung Cancer (NSCLC): a Retrospective Observational Study
研究名称(中文):PAXOS(中国)- 早期非小细胞肺癌(NSCLC)患者接受辅助
讲者:Chenlei Zhang|沈阳,中国
摘要号:916P
研究名称(英文):Adjuvant therapy with anlotinib for non-pCR non-small cell lung cancer after neoadjuvant immunochemotherapy: A prospective study.
研究名称(中文):新辅助免疫化疗后非病理完全缓解非小细胞肺癌的辅助安罗替尼治疗:一项前瞻性研究
讲者:Jie Xu|天津,中国
摘要号:917P
研究名称(英文):Aumolertinib as adjuvant therapy for patients with resected EGFR-mutated stage I NSCLC: A retrospective real-world study
研究名称(中文):阿美替尼作为切除后EGFR突变I期非小细胞肺癌患者的辅助治疗:一项回顾性真实世界研究
讲者:Jianyuan J. Huang|福州,中国
摘要号:918P
研究名称(英文):Prospective dynamic molecular residual disease analysis of perioperative nivolumab in resectable NSCLC: data from the CTONG1804 phase 2 clinical trial
研究名称(中文):可切除非小细胞肺癌围手术期纳武利尤单抗的前瞻性动态分子残留病灶分析:CTONG1804 II期临床试验数据
讲者:Wei-Chi Luo|广州,中国
摘要号:919P
研究名称(英文):Leveraging ctDNA-MRD for Prognostic Stratification, Adjuvant Therapy Guidance, and Multi-Dimensional Risk Model Construction in Postoperative Stage I-III NSCLC Patients
研究名称(中文):利用ctDNA-MRD在术后I-III期非小细胞肺癌患者中进行预后分层、辅助治疗指导和多维风险模型构建
讲者:Xiling Shi|南京,中国
摘要号:921P
研究名称(英文):Recurrence Gene Profiles of Adjuvant Osimertinib in Early-Stage EGFRm NSCLC: A Multicenter Real-World Study (RAISE)
研究名称(中文):早期EGFR突变非小细胞肺癌辅助奥希替尼的复发基因谱:一项多中心真实世界研究(RAISE)
讲者:Liang Zeng|长沙,中国
摘要号:922P
研究名称(英文):Early Peripheral T-Lymphocyte Changes After Minimally Invasive Lung Cancer Surgery and Their Relation to the Extent of Lymph Node Dissection
研究名称(中文):微创肺癌手术后外周T淋巴细胞早期变化及其与淋巴结清扫范围的关系
讲者:Jieshuo Wang|广州,中国
摘要号:923P
研究名称(英文):First real-world experience of adjuvant lorlatinib in resected high-risk stage I ALK-positive non-small-cell lung cancer: feasibility and tolerability
研究名称(中文):首次真实世界经验:洛拉替尼辅助治疗已切除的高危 I 期 ALK 阳性非小细胞肺癌:可行性与耐受性
讲者:Yudong Zhang|广州,中国
摘要号:925P
研究名称(英文):Mechanistic Study of the MYC/CTPS1/ATR Axis as a Targetable Therapeutic Vulnerability in MYC-Driven Lung Adenocarcinoma
研究名称(中文):MYC/CTPS1/ATR轴作为MYC驱动肺腺癌可靶向治疗脆弱性的机制研究
讲者:Jiayue Ye|杭州,中国
摘要号:927P
研究名称(英文):From Discovery to Clinical Implementation: DNA Methylation Biomarkers in Non-Small Cell Lung Cancer, 1999–2025
研究名称(中文):从发现到临床实施:非小细胞肺癌中的DNA甲基化生物标志物,1999–2025
讲者:Chen Chen|长沙,中国
摘要号:929eP
研究名称(英文):Cross-body-site microbial source–sink dynamics reveal a mobile microbiome assemblage in lung cancer
研究名称(中文):跨身体部位微生物源-汇动态揭示肺癌中的移动微生物组群落
讲者:Lu Wang|上海,中国
摘要号:931eTiP
研究名称(英文):Adjuvant Aumolertinib with or without Platinum-Based Chemotherapy for EGFR-Sensitive Mutant NSCLC with Co-Mutations in Stage II-IIIA: A Prospective Randomized Controlled Trial
研究名称(中文):EGFR敏感突变伴共突变的II-IIIA期非小细胞肺癌阿美替尼联合或不联合铂类化疗辅助治疗:前瞻性随机对照试验
讲者:Guoyu Zhang|洛阳,中国
局部晚期胸部肿瘤
摘要号:934P
研究名称(英文):High pathological response rate of neoadjuvant arterial infusion chemotherapy combined with immunotherapy in initially unresectable stage IIIB non-small cell lung cancer: an open-label, single-arm, phase II trial
研究名称(中文):初始不可切除IIIB期非小细胞肺癌新辅助动脉灌注化疗联合免疫治疗获得高病理缓解率:一项开放标签、单臂、II期试验
讲者:Xu Ma|上海,中国
摘要号:935P
研究名称(英文):Surgical and Survival Benefits of Neoadjuvant Targeted Therapy versus Chemoimmunotherapy in Lung Adenocarcinoma: A Dual-center Research
研究名称(中文):肺腺癌新辅助靶向治疗对比化疗免疫治疗的生存与手术获益:一项双中心研究
讲者:Jiaxi Xu|北京,中国
摘要号:936P
研究名称(英文):Efficacy and Safety of Serplulimab Plus Chemotherapy as First-Line Treatment for Pulmonary Neuroendocrine Neoplasms (PNENs): A Real-World Retrospective Study
研究名称(中文):斯鲁利单抗联合化疗一线治疗肺神经内分泌肿瘤(PNENs)的有效性和安全性:一项真实世界回顾性研究
讲者:Guan Ming Jiang|东莞,中国
摘要号:937P
研究名称(英文):SLC40A1+ macrophages act as antigen-presenting cells in EGFR-mutant patients exhibiting resistance to tyrosine kinase inhibitors
研究名称(中文):SLC40A1阳性巨噬细胞在酪氨酸激酶抑制剂耐药的EGFR突变患者中发挥抗原呈递细胞作用
讲者:Shuxin Zhu|上海,中国
摘要号:939P
研究名称(英文):Double-Dose Furmonertinib Retreatment After Resistance to EGFR-TKIs in Postoperative Recurrent Lung Adenocarcinoma: Efficacy and Impact of High-Risk Histological Patterns
研究名称(中文):双剂量福莫替尼在EGFR-TKI耐药后术后复发性肺腺癌中的再治疗:疗效与高危组织学模式的影响
讲者:Yucheng Ma|杭州,中国
摘要号:940P
研究名称(英文):Therapeutic differences associated with fusion partner heterogeneity in fusion-positive lung adenocarcinoma: a real-world cohort study
研究名称(中文):与融合阳性肺腺癌融合伴侣异质性相关的治疗差异:一项真实世界队列研究
讲者:Zihan Sun|北京,中国
摘要号:941P
研究名称(英文):Single-Cell Transcriptomics and In Silico Knockout Reveal ELK1 Involvement in Ferroptosis in Lung Adenocarcinoma
研究名称(中文):单细胞转录组学与计算机模拟敲除揭示ELK1参与肺腺癌铁死亡
讲者:Zihao Li|杭州,中国
摘要号:942P
研究名称(英文):RET Fusion–Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-mutation Profiles, and Implications for Targeted and Immunotherapy
研究名称(中文):RET融合阳性肺腺癌:伴侣特异性临床病理特征、共突变谱及对靶向治疗和免疫治疗的启示
讲者:Zihan Sun|北京,中国
摘要号:944eP
研究名称(英文):Pathomics-Based Random Forest Modeling for Prediction of ALK Mutation Status in Non-Small Cell Lung Cancer
研究名称(中文):基于病理组学的随机森林模型预测非小细胞肺癌ALK突变状态
讲者:Eva Yi Wah Cheung|香港,中国香港
转移性胸部肿瘤
摘要号:952P
研究名称(英文):Efficacy and Safety of De-escalated First-line Immunotherapy Regimens in Older Patients with NSCLC: A Real-world Comparative Study
研究名称(中文):降阶梯一线免疫治疗方案在老年非小细胞肺癌患者中的有效性和安全性:一项真实世界比较研究
讲者:Hualin Chen|湛江,中国
摘要号:954P
研究名称(英文):Phase II Study of Serplulimab Plus Bevacizumab and Chemotherapy in Advanced Non-Squamous NSCLC Progressing on Prior Immunotherapy
研究名称(中文):II期研究:斯鲁利单抗联合贝伐珠单抗和化疗治疗既往免疫治疗后进展的晚期非鳞状非小细胞肺癌
讲者:Jianhua Chang|深圳,中国
摘要号:955P
研究名称(英文):First-Line Serplulimab-Based Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Prospective Real-World ASTRUM-002R Study
研究名称(中文):局部晚期或转移性非小细胞肺癌的斯鲁利单抗为基础一线治疗:一项前瞻性真实世界ASTRUM-002R研究
讲者:Jianya Zhou|杭州,中国
摘要号:956P
研究名称(英文):Tumor Response Dynamics of Atezolizumab plus Bevacizumab and Chemotherapy in the Asian Subgroup of the Phase III IMpower150 Trial
研究名称(中文):III期 IMpower150试验亚洲亚组中阿替利珠单抗联合贝伐珠单抗和化疗的肿瘤反应动态
讲者:Wen-Chien Cheng|台中,中国台湾
摘要号:957P
研究名称(英文):Post-hoc Analysis of Squamous Subgroup from the CAMPASS Trial: Benmelstobart plus Anlotinib vs Pembrolizumab in First-Line PD-L1-Positive Advanced NSCLC
研究名称(中文):CAMPASS试验鳞状细胞亚组的事后分析:Benmelstobart联合安罗替尼对比帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌
讲者:Baohui Han|上海,中国
摘要号:958P
研究名称(英文):Efficacy and safety of sevabertinib in Chinese patients with HER2-mutant non-small cell lung cancer (NSCLC) in the SOHO-01 study
研究名称(中文):SOHO-01研究中sevabertinib在中国HER2突变非小细胞肺癌(NSCLC)患者中的疗效和安全性
讲者:董晓荣|华中科技大学同济医学院附属同济医院
摘要号:959P
研究名称(英文):Durvalumab+Anlotinib vs. Durvalumab monotherapy Maintenance in ES-SCLC: Final OS and Biomarker Analysis of Phase 2 DURABLE Trial
研究名称(中文):Durvalumab联合Anlotinib与Durvalumab单药维持治疗用于广泛期小细胞肺癌的比较:II期DURABLE试验的最终总生存期和生物标志物分析
讲者:Baohui Han|上海,中国
摘要号:960P
研究名称(英文):Long-Term Follow-up of Overall Survival from Phase 2 Randomized Dose Optimization Study of Alveltamig (ZG006), a DLL3/DLL3/CD3 Trispecific T Cell Engager, as Monotherapy in Advanced Small Cell Lung Cancer
研究名称(中文):Alveltamig(ZG006)(一种DLL3/DLL3/CD3三特异性T细胞接合剂)单药治疗晚期小细胞肺癌的II期随机剂量优化研究总体生存长期随访
讲者:Xinghao Ai|上海,中国
摘要号:961P
研究名称(英文):A retrospective, multinational real-world study evaluating the effectiveness of Tarlatamab in patients with ES-SCLC treated under Expanded Access Programs in Korea and Taiwan
研究名称(中文):一项评估在韩国和中国台湾地区扩展访问项目中接受Tarlatamab治疗的广泛期小细胞肺癌患者有效性的回顾性、多国真实世界研究
讲者:Shang-gin Wu|台北,中国台湾
摘要号:966P
研究名称(英文):Vebreltinib in combination with firmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET amplification: Results from a phase Ib/II trial
研究名称(中文):Vebreltinib联合Firmonertinib治疗局部晚期或转移性EGFR突变且MET扩增的非小细胞肺癌(NSCLC):一项Ib/II期研究结果
讲者:Yan Zhang|成都,中国
摘要号:969P
研究名称(英文):Clinical and Molecular Characterizations Across Different PD-L1 Expression Classes in EGFR-Mutant NSCLC: A Real-World Study
研究名称(中文):不同 PD-L1 表达分类下 EGFR 突变非小细胞肺癌的临床和分子特征:一项真实世界研究
讲者:Ran Huo|保定,中国
摘要号:970P
研究名称(英文):Post-progression genomic landscapes following EGFR-TKI plus chemotherapy versus monotherapy in EGFR-mutant NSCLC
研究名称(中文):EGFR-TKI联合化疗对比单药治疗在EGFR突变非小细胞肺癌进展后的基因组图谱
讲者:Xiaohuan Zhou|广州,中国
摘要号:971P
研究名称(英文):Phase 1 Study of EGFR Degrader, BG-60366, in Previously Treated EGFR-Mutant Non–Small Cell Lung Cancer (EGFRmut NSCLC)
研究名称(中文):EGFR降解剂BG-60366在既往治疗过的EGFR突变非小细胞肺癌(EGFRmut NSCLC)中的1期研究
讲者:吴一龙|广州,中国
摘要号:972P
研究名称(英文):Third-generation EGFR mutation targeted drug-Osimertinib, Furmonertinib and Aumolertinib improved the prognosis of stage IV non-small-cell lung cancer
研究名称(中文):第三代EGFR突变靶向药物-奥希替尼、伏美替尼和阿美替尼改善了IV期非小细胞肺癌的预后
讲者:Honghong Zhu|衢州,中国
摘要号:973P
研究名称(英文):Firmonertinib plus 4 cycles platinum-pemetrexed as first-line treatment for EGFR-mutant locally advanced or metastatic NSCLC(FLAMES)
研究名称(中文):Firmonertinib联合4周期铂类-培美曲塞作为EGFR突变局部晚期或转移性非小细胞肺癌一线治疗(FLAMES)
讲者:Lemeng Zhang|长沙,中国
摘要号:975P
研究名称(英文):Andamertinib Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced NSCLC with Non-Classical EGFR Mutations: A Preliminary Analysis
研究名称(中文):Andamertinib联合铂类化疗作为非经典EGFR突变晚期NSCLC的一线治疗:一项初步分析
讲者:方文峰|广州,中国
摘要号:977P
研究名称(英文):Treatment Patterns and Effectiveness of First-Line Osimertinib Combined with Diverse CTx in Chinese EGFR-Mutant NSCLC Patients with CNS Metastases: data from a Multicenter Prospective Real-World Study (FOREFRONT)
研究名称(中文):中国EGFR突变伴中枢神经系统转移非小细胞肺癌患者一线奥希替尼联合多种化疗的治疗模式及有效性:一项多中心前瞻性真实世界研究(FOREFRONT)数据
讲者:Qiming Wang|郑州,中国
摘要号:978P
研究名称(英文):Serplulimab Combined with Bevacizumab and Chemotherapy in EGFR-TKI-Resistant Non-Squamous Non-Small Cell Lung Cancer with Brain Metastases: A Prospective, Multicenter, Single-Arm Study
研究名称(中文):斯鲁利单抗联合贝伐珠单抗和化疗治疗EGFR-TKI耐药的非鳞状非小细胞肺癌伴脑转移:一项前瞻性、多中心、单臂研究
讲者:Shen Cun Fang|南京,中国
摘要号:979P
研究名称(英文):PD‑L1 as a Negative Prognostic Biomarker and Positive Predictive Marker for Chemotherapy Intensification in EGFR‑Mutant NSCLC: A Real‑World Study
研究名称(中文):PD-L1作为EGFR突变非小细胞肺癌化疗强化的负性预后生物标志物和正性预测标志物:一项真实世界研究
讲者:Xuuewu Wei|广州,中国
摘要号:980eP
研究名称(英文):Patterns of first progression and CNS failure after aumolertinib in EGFR-mutant advanced NSCLC: a real-world cohort study
研究名称(中文):EGFR突变型晚期非小细胞肺癌使用aumolertinib后首次进展及中枢神经系统失败模式:一项真实世界队列研究
讲者:Xianjing Chu|长沙,中国
摘要号:981P
研究名称(英文):Impact of Radiofrequency Ablation on Disease Progression Patterns and CNS Metastasis Risk in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (ABLATE Study)
研究名称(中文):射频消融对EGFR突变晚期非小细胞肺癌疾病进展模式和中枢神经系统转移风险的影响(ABLATE研究)
讲者:Jin Sheng|杭州,中国
摘要号:984P
研究名称(英文):Aumolertinib in Combination with Radiotherapy for EGFR-Mutant Stage IV NSCLC with Oligoprogressive or Slow Progression: A Prospective Phase II Study
研究名称(中文):阿美替尼联合放疗治疗EGFR突变寡进展或缓慢进展IV期非小细胞肺癌:一项前瞻性II期研究
讲者:Yingying Zhang|济南,中国
摘要号:985P
研究名称(英文):Longitudinal single-cell profiling in EGFR-mutant NSCLC treated with osimertinib and sacituzumab tirumotecan
研究名称(中文):接受奥希替尼和sacituzumab tirumotecan治疗的EGFR突变型非小细胞肺癌的纵向单细胞谱分析
讲者:Jingsong Cheng|广州,中国
摘要号:988P
研究名称(英文):From clinical phenotype to metabolic vulnerability: multi-omics profiling of EGFR-TKI-associated brain metastases in EGFR-mutant NSCLC
研究名称(中文):从临床表型到代谢脆弱性:EGFR突变非小细胞肺癌中EGFR-TKI相关脑转移的多组学谱分析
讲者:Xinyu Wang|北京,中国
摘要号:990P
研究名称(英文):Impact of Post-Resistance Molecular Retesting Strategies on Treatment Delivery and Clinical Outcomes After EGFR-TKI Resistance in Advanced EGFR-Mutant NSCLC: A Real-World Study
研究名称(中文):EGFR-TKI耐药后分子再检测策略对晚期EGFR突变非小细胞肺癌治疗给药及临床结局的影响:一项真实世界研究
讲者:Wenting Zhang|福州,中国
摘要号:991P
研究名称(英文):Global trends in the management of first-line (1L) and second-line (2L) treatment in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): A real-world study
研究名称(中文):全球一线(1L)和二线(2L)治疗在EGFR突变(EGFRm)晚期非小细胞肺癌(NSCLC)中的管理趋势:一项真实世界研究
讲者:Hua Zhong|上海,中国
摘要号:992P
研究名称(英文):Prognostic Value of Intrathoracic Metastatic Patterns in M1b–M1c2 EGFR-Mutant Non-Small Cell Lung Cancer
研究名称(中文):M1b–M1c2 EGFR突变非小细胞肺癌胸内转移模式的预后价值
讲者:Yunchang Meng|成都,中国
摘要号:993P
研究名称(英文):Association of Recombinant Zoster Vaccination With Reduced Mortality and Cardiopulmonary Events in Patients With Lung Cancer: A Real-World Propensity Score-Matched Study
研究名称(中文):重组带状疱疹疫苗接种与肺癌患者死亡率及心肺事件减少的关联:一项真实世界倾向评分匹配研究
讲者:Shu-Farn Tey|台南,中国台湾
摘要号:994P
研究名称(英文):Clinicopathologic Features of MTAP loss in advanced NSCLC with Actionable genomic alterations
研究名称(中文):MTAP缺失在具有可操作基因改变的晚期非小细胞肺癌中的临床病理特征
讲者:Anna Li|广州,中国
摘要号:996P
研究名称(英文):Lorlatinib in ALK-positive advanced NSCLC: a real-world, multicenter study within a hub-and-spoke collaborative network across core and primary hospitals in China
研究名称(中文):洛拉替尼在ALK阳性晚期非小细胞肺癌中的真实世界多中心研究:中国核心与基层医院之间的枢纽-辐条协作网络研究
讲者:Puyuan Xing|北京,中国
摘要号:998P
研究名称(英文):First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy with or without Chemotherapy for Patients with MET-Altered Advanced Non-Small-Cell Lung Cancer: A Multicentre Retrospective Cohort Study
研究名称(中文):一线MET酪氨酸激酶抑制剂对比免疫治疗联合或不联合化疗治疗MET改变晚期非小细胞肺癌患者:一项多中心回顾性队列研究
讲者:Shengling Hu|成都,中国
摘要号:999P
研究名称(英文):Efficacy and safety of resencatinib (HS-10365) in patients with RET fusion-positive NSCLC: A pooled analysis
研究名称(中文):RET融合阳性非小细胞肺癌患者中resencatinib(HS-10365)的疗效与安全性:一项汇总分析
讲者:Zhen Zhou|上海,中国
摘要号:1000P
研究名称(英文):Comprehensive MultIomics Characterization of STK11/LKB1-Mutant Lung Cancer
研究名称(中文):STK11/LKB1突变肺癌的全面多组学特征
讲者:Zhengyang -. Yan|深圳,中国
摘要号:1002P
研究名称(英文):Efficacy and Safety of Sacituzumab Tirumotecan in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer
研究名称(中文):Sacituzumab Tirumotecan治疗晚期非鳞状非小细胞肺癌的有效性和安全性
讲者:Haifeng Qin|北京,中国
摘要号:1003P
研究名称(英文):Combined Efficacy of Radioactive Iodine-125 Seed Brachytherapy and Radiofrequency Ablation for Thoracic Malignancies
研究名称(中文):放射性碘-125粒子近距离放疗联合射频消融治疗胸部恶性肿瘤的疗效
讲者:Dengyao Liu|乌鲁木齐,中国
摘要号:1005P
研究名称(英文):Real-world rwPFS comparison of IAC, AC and IC regimens in advanced lung adenocarcinoma: A single-center retrospective cohort with IPTW and PSM adjustment
研究名称(中文):真实世界无进展生存期(rwPFS)比较IAC、AC和IC方案在晚期肺腺癌中的疗效:一项采用IPTW和PSM调整的单中心回顾性队列
讲者:Xiaofang Li|保定,中国
摘要号:1007P
研究名称(英文):Longitudinal peripheral blood immune profiling and treatment response prediction in patients with advanced non-small cell lung cancer receiving first-line immunotherapy
研究名称(中文):晚期非小细胞肺癌接受一线免疫治疗患者的纵向外周血免疫谱分析与治疗应答预测
讲者:Zimo Zhao|沈阳,中国
摘要号:1009P
研究名称(英文):Unecritinib versus crizotinib in ROS1-positive advanced non-small cell lung cancer: a matching-adjusted indirect comparison
研究名称(中文):ROS1阳性晚期非小细胞肺癌中Unecritinib对比Crizotinib:一项匹配校正的间接比较研究
讲者:Ziming Li|上海,中国
摘要号:1010P
研究名称(英文):Matching-adjusted indirect comparison of unecritinib versus entrectinib in patients with ROS1-positive advanced non-small cell lung cancer
研究名称(中文):ROS1阳性晚期非小细胞肺癌患者中unecritinib与entrectinib的匹配调整间接比较
讲者:李子明|上海,中国
摘要号:1011P
研究名称(英文):An AI-derived dynamic ctDNA framework for molecular response stratification in advanced NSCLC
研究名称(中文):一种AI衍生的动态ctDNA框架,用于晚期NSCLC的分子应答分层
讲者:Si-Yang M. Liu|广州,中国
摘要号:1013P
研究名称(英文):Efficacy and Safety of Ametinib as First-Line Treatment in EGFR-Positive NSCLC Patients with Respiratory Comorbidities: A Retrospective Real-World Analysis
研究名称(中文):Ametinib作为一线治疗在合并呼吸系统共病的EGFR阳性非小细胞肺癌患者中的疗效与安全性:一项回顾性真实世界分析
讲者:Xin Gan|南昌,中国
摘要号:1015TiP
研究名称(英文):Implementation and independent benchmarking of a provenance-anchored AI harness for thoracic multidisciplinary team decision support
研究名称(中文):溯源锚定的人工智能框架在胸部多学科团队决策支持中的实施与独立基准测试
讲者:Yi Yang|成都,中国
摘要号:1017TiP
研究名称(英文):Sacituzumab Tirumotecan Combined with Aumolertinib as First-Line Therapy in Patients with Advanced EGFR-Mutant NSCLC and High PD-L1 Expression
研究名称(中文):Sacituzumab Tirumotecan联合Aumolertinib作为晚期EGFR突变非小细胞肺癌伴PD-L1高表达患者的一线治疗
讲者:Yanhong Shang|保定,中国
摘要号:1018eP
研究名称(英文):Efficacy and Safety of Recombinant Human Endostatin Combined with PD-1 Inhibitors in Previously Treated Advanced Squamous Non-Small Cell Lung Cancer: A Prospective Single-Arm Study
研究名称(中文):重组人内皮抑素联合PD-1抑制剂治疗既往接受治疗的晚期鳞状非小细胞肺癌的疗效和安全性:一项前瞻性单臂研究
讲者:Lei Mi|盐城,中国
摘要号:1019eP
研究名称(英文):First-Line Toripalimab in Combination with Platinum-Doublet Chemotherapy for Advanced B3 Thymoma and Thymic Carcinoma: An Open-Label Prospective Phase Ⅱ Trial
研究名称(中文):一线特瑞普利单抗联合铂类双药化疗治疗晚期B3胸腺瘤和胸腺癌:一项开放标签前瞻性Ⅱ期试验
讲者:Xingsheng Hu|北京,中国
摘要号:1020eP
研究名称(英文):Beyond a fixed cut-off: gray-zone management of NGS-detected MET amplification in real-world NSCLC practice
研究名称(中文):超越固定截断值:真实世界非小细胞肺癌实践中基于NGS检测MET扩增的灰区管理
讲者:Wei Rao|北京,中国
摘要号:1023eP
研究名称(英文):Real-world Efficacy and Safety of First-Line Third-Generation EGFR-TKI Combined with Chemotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
研究名称(中文):真实世界中一线第三代EGFR-TKI联合化疗治疗晚期EGFR突变非小细胞肺癌的有效性和安全性
讲者:Rongyu Zhang|青岛,中国
摘要号:1024eP
研究名称(英文):Evaluating the Precision of 3D-Printing Template Technology in Iodine-125 Seed Implantation for Lung Metastases: A Retrospective Study.
研究名称(中文):评估3D打印模板技术在碘-125粒子植入治疗肺转移瘤中的精准度:一项回顾性研究
讲者:Dengyao Liu|乌鲁木齐,中国
摘要号:1025eP
研究名称(英文):Atezolizumab (atezo) in patients (pts) with high PD-L1 1L stage IV NSCLC: a Phase III multicenter trial in China
研究名称(中文):阿替利珠单抗(atezo)治疗高PD-L1一线IV期非小细胞肺癌患者:中国一项III期多中心试验
讲者:Shun Lu|上海,中国
摘要号:1029eP
研究名称(英文):High-dose Furmonertinib in first-line treatment of patients with EGFR classically mutated advanced NSCLC
研究名称(中文):高剂量Furmonertinib一线治疗EGFR经典突变晚期非小细胞肺癌患者
讲者:Lu Zhang|武汉,中国
摘要号:1033eP
研究名称(英文):Treatment Patterns, Patient Characteristics and Clinical Outcomes Among Patients with Transformed Small Cell Lung Cancer: A Systematic Literature Review
研究名称(中文):转化性小细胞肺癌患者的治疗模式、患者特征和临床结局:一项系统性文献综述
讲者:James Chih-Hsin Yang|台北,中国台湾
摘要号:1035eP
研究名称(英文):Prognosis Analysis in Oligometastatic NSCLC with Systemic Therapy and Iodine-125 Seed Implantation: A Retrospective Study
研究名称(中文):寡转移性非小细胞肺癌系统性治疗与碘-125粒子植入的预后分析:一项回顾性研究
讲者:Dengyao Liu|乌鲁木齐,中国
摘要号:1037eP
研究名称(英文):LncRNA CHRM3-AS2 Reprograms Tumor-Associated Macrophages via Exosomal Delivery and PI3Kγ Ubiquitination to Suppress Lung Adenocarcinoma Progression
研究名称(中文):长链非编码RNA CHRM3-AS2通过外泌体递送和PI3Kγ泛素化重编程肿瘤相关巨噬细胞以抑制肺腺癌进展
讲者:Chuandong Zhu|南京,中国
摘要号:1038eP
研究名称(英文):The HIF‑1α/METTL3/c‑Myc Axis Promotes Vasculogenic Mimicry to Facilitate Malignant Progression in Non‑Small Cell Lung Cancer
研究名称(中文):HIF-1α/METTL3/c-Myc轴通过促进血管拟态促进非小细胞肺癌恶性进展
讲者:Lin Wang|南京,中国
摘要号:1039eTiP
研究名称(英文):ctDNA Clearance-Guided Chemotherapy De-escalation in First-Line Aumolertinib-Based Regimen for Advanced EGFR-Mutant NSCLC: A Phase II, Single-Arm, Prospective Trial
研究名称(中文):ctDNA清除指导的一线Aumolertinib方案化疗降阶梯治疗用于晚期EGFR突变NSCLC:一项II期、单臂、前瞻性试验
讲者:Fanlu Meng|天津,中国
摘要号:1040eTiP
研究名称(英文):Aumolertinib combined with bevacizumab and pemetrexed as first-line treatment for EGFR-sensitive mutated NSCLC with brain or leptomeningeal metastases: An open-label, single-center, observational study
研究名称(中文):阿美替尼联合贝伐珠单抗和培美曲塞作为EGFR敏感突变伴脑或软脑膜转移的非小细胞肺癌一线治疗:一项开放标签、单中心、观察性研究
讲者:Qichuan Wang|南阳,中国
摘要号:1041eTiP
研究名称(英文):Management strategy of 1L Lorlatinib with Hyperlipidemia in Stage IIIB-IV ALK positive NSCLC: A multi-center prospective study in China
研究名称(中文):一线Lorlatinib合并高脂血症治疗IIIB-IV期ALK阳性非小细胞肺癌的管理策略:中国多中心前瞻性研究
讲者:张力|中山大学肿瘤防治中心
摘要号:1042eTiP
研究名称(英文):A prospective, single-arm, phase II clinical trial of high-dose Aumolertinib combined with Ommaya reservoir and ventriculoperitoneal shunt in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis
研究名称(中文):一项前瞻性、单臂、II期临床试验,比较高剂量Aumolertinib联合Ommaya储液囊和脑室腹腔分流术治疗EGFR突变伴软脑膜转移的非小细胞肺癌
讲者:Suzhen Wang|济南,中国
来源:ESMO Asia
审核:Lena
排版:Eira
执行:Lena